Status note CHASE Phase 2b trial did not meet primary endpoints; development of KPI-012 and the MSC-S platform discontinued by September 2025. Had received Orphan Drug and Fast Track designations for PCED (April 2023).
KPI-014
Stage not disclosed · ActiveModality: mesenchymal stem cell secretome (MSC-S)
Status note Legacy portfolio asset; the company is preserving and seeking to monetize via licensing/collaboration. No ongoing clinical trials as of June 30, 2026; preclinical activities contingent on funding and partners.
Per-asset detail extracted from the 10-Q filed 2026-08-19. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Institutional holders
Fund
Shares
Q/Q change
% of portfolio
Filing
ADAR1 Capital Management
0
-141,480
0.00%
2026-08-14
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.